Phase III EMERALD trial (NCT03778931) demonstrated improving rate of progression-free survival (PFS), in randomized ER+/HER2–advanced BC patients harboring ESR1 activating mutations under elacestrant (oral SERD) in comparison with standard of care (SOC) [2,10]. Here, ERBB2 is linked to breast cancer.